Drugs / 7MW3711
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07466160 | Feb 2026 → Dec 2027 expected | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06008366 | Sep 2023 → Aug 2025 | neoplasm | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT06008379 | Aug 2023 → Aug 2025 | neoplasm | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07831863 | Oct 2026 → Mar 2029 expected | squamous cell lung carcinoma | Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 7MW3711 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06008379 ↗ |
| Modality | Other / unclassified | “7MW3711 is an antibody-drug conjugate(ADC) directed to a target wildly expressed on solid tumors.” NCT06008366 ↗ |
| Route | Intravenous | “IV administration of 7MW3711” NCT06008366 ↗ |